Industry: Healthcare
Published Date: January-2025
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 191
Report ID: PMRREP32139
The global intravascular lithotripsy (IVL) market is estimated to reach a value of US$ 1197.5 Mn in 2031 from a value of US$ 489.1 Mn recorded in 2024. It is likely to showcase a CAGR of 11.7% during the forecast period from 2024 to 2031.
It is anticipated that the prevalence of calcified arterial problems would increase as the world's population ages. IVL's demand is further surged by the fact that it effectively treats older patients who might not be able to handle invasive procedures. The number of people aged 65 and older in the U.S. is projected to reach 80 million by 2040, significantly increasing the pool of patients who could benefit from IVL.
-market-outlook_01.jpg)
Key Highlights of the Market
|
North America’s market generated a significant share of 40.1% in 2024. It was driven by rising incidence of cardiovascular diseases and developments in minimally invasive procedures. Increasing adoption of IVL systems in treating complex calcified lesions ensures effective patient outcomes, fueling market growth.
The region also benefits from robust healthcare infrastructure, high healthcare spending, and strong regulatory support, particularly in the U.S. Moreover, ongoing clinical trials and strategic collaborations among key players solidify the region’s position, fostering innovation and extending accessibility across North America.
The coronary intravascular lithotripsy systems segment maintains a dominant position in the market, accounting for 61.2% of the share in 2024. Growth is attributed to their effectiveness in treating complex calcified coronary lesions, which are often difficult to address with traditional angioplasty techniques.
IVL systems utilize focused shockwaves to break down calcium buildup, improving vessel compliance and enabling better stent placement. With a rising prevalence of coronary artery disease (CAD) and an increasing demand for minimally invasive treatments, coronary IVL systems are expected to maintain strong market demand. Consequently, driving innovation and expanding market share among leading manufacturers.
The coronary artery disease segment maintains primacy in the market accounting for a substantial 54.1% market share. The growth is due to rising incidences of lifestyle-related factors such as obesity, smoking, and sedentary habits contribute to the growing CAD patient population. Advanced diagnostic and therapeutic technologies, including minimally invasive procedures, play a crucial role in addressing this burden.
Increasing awareness about early diagnosis and proactive management of CAD is fostering segment growth. Favorable reimbursement policies and strategic investments in innovative treatment options, such as intravascular lithotripsy (IVL), enhance patient outcomes, reinforcing the dominance. Key players focus on expanding their product portfolios to sustain leadership.
The intravascular lithotripsy (IVL) market is gaining significant traction, particularly in the treatment of coronary artery disease (CAD). IVL, a minimally invasive technique, uses shockwaves to break down calcified plaque in arteries, improving blood flow and allowing for better stent placement.
As cardiovascular diseases continue to rise globally, the demand for advanced, effective treatment options like IVL is increasing. The market is experiencing rapid growth, driven by technological advancements, an aging population, and the rising prevalence of lifestyle-related risk factors such as obesity and diabetes.
Key players in the market are focusing on improving the safety and efficiency of IVL systems, leading to enhanced patient outcomes and high adoption rates. North America holds a dominant share, fueled by strong healthcare infrastructure, high levels of awareness, and favorable reimbursement policies. The growing trend toward minimally invasive treatments is expected to further propel market expansion in the coming years.
-market-insights-and-key-trends_001.jpg)
The intravascular lithotripsy (IVL) market has witnessed significant growth over recent years, driven by technological innovations and the increasing prevalence of cardiovascular diseases. Historically, traditional treatments for coronary artery disease (CAD), such as balloon angioplasty, were less effective for calcified lesions.
The introduction of IVL systems revolutionized the treatment of these complex lesions by using shockwaves to safely break down calcifications, improving patient outcomes and enhancing the stent deployment process. Currently, the IVL market is expanding rapidly due to the increasing adoption of minimally invasive procedures, particularly in developed regions like North America and Europe.
Healthcare providers are increasingly opting for IVL due to its proven efficacy and reduced risk of complications compared to traditional methods. Additionally, advancements in IVL technology, such as improved shockwave delivery systems, have enhanced their accessibility and affordability, further driving market growth.
The IVL market is expected to continue growing, fueled by an aging global population, higher CAD prevalence, and ongoing advancements in medical devices. Emerging markets, particularly in Asia Pacific and Latin America, present untapped opportunities for expansion. The market is poised for further innovation, with the development of next-generation IVL systems designed for broader applications, promising even better clinical outcomes.
Increasing Prevalence of Vascular Calcification
The increasing prevalence of vascular calcification remains a key driver for intravascular lithotripsy (IVL) market. Vascular calcification, which is linked to aging and chronic diseases such as diabetes, kidney disease, and hypertension, is becoming more common, affecting up to 30-40% of adults over 65 years old. This condition leads to arterial stiffening, heightening the risk of heart attacks, strokes, and other cardiovascular events.
As awareness of the condition’s impact on cardiovascular health rises, so does the demand for effective, minimally invasive treatments like IVL. IVL technology, which uses shockwaves to break down calcified plaques, offers a safe alternative to traditional methods.
The global market for IVL is expected to grow at an annual rate of 8-10%, with advancements in medical devices and treatment efficacy and growing elderly population and increasing rates of vascular calcification. The rising prevalence of vascular calcification is expected to continue to fuel the demand for innovative treatments, making it a critical factor for market growth in the coming years.
In June 2024, AVS received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin its pivotal trial for Pulse IVL™. This study will evaluate the safety and efficacy of the system in treating U.S.-based patients with severely calcified peripheral arterial disease.
Patient Preference for Minimally Invasive Cardiovascular Treatments
Patient preference for minimally invasive cardiovascular treatments is a significant fueling factor for intravascular lithotripsy (IVL) market growth, particularly for procedures like intravascular lithotripsy (IVL). These treatments offer numerous benefits over traditional methods, including shorter recovery times, reduced risk of complications, and minimal discomfort.
As patients become more informed about their healthcare options, there is a growing demand for less invasive procedures that offer fast healing and few post-operative restrictions. This trend is especially prominent among elderly patients and those with comorbidities, who may be at higher risk for complications with open surgeries.
The shift towards minimally invasive treatments is further supported by advancements in medical technology, improving both safety and efficacy. Consequently, the preference for these options is propelling the growth of the cardiovascular treatment market, with continued innovation and patient-centric care driving adoption rates. This trend is expected to sustain its momentum as healthcare providers prioritize patient comfort and quicker recovery times in their treatment protocols.
High Costs of Intravascular Lithotripsy Devices Limit Accessibility
The high costs of intravascular lithotripsy (IVL) devices represent a significant restraint in expanding their accessibility. Due to the advanced technology and precision required, these devices come with a high price tag, which makes them unaffordable for many healthcare facilities, especially those in developing regions or those with limited resources.
The cost barrier is passed on to patients, which may result in increased out-of-pocket expenses. Additionally, insurance coverage for IVL treatments may be limited, further hindering access for many individuals. As a result, the high costs of IVL devices remain a key challenge for broad market adoption and treatment accessibility.
Growing Adoption in Emerging Healthcare Markets
Emerging healthcare markets present significant opportunities in the intravascular lithotripsy (IVL) market. As healthcare infrastructure improves in developing regions, there is increasing access to advanced medical technologies, which drives demand for innovative treatments like IVL.
Rising awareness of cardiovascular diseases and the growing burden of conditions like vascular calcification in these markets further contribute to the adoption of minimally invasive procedures. Healthcare providers in these regions are prioritizing cost-effective, patient-friendly treatments that offer quick recovery times. These factors create a favorable environment for the expansion of IVL technologies, making emerging healthcare markets key growth areas for the industry.
Integration of Imaging Modalities for Enhanced IVL Precision
The integration of imaging modalities, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), with intravascular lithotripsy (IVL) procedures enhances precision and outcomes. These imaging techniques allow for real-time visualization of calcified plaques, improving lesion assessment and treatment planning. By providing detailed, high-resolution images, they guide the accurate placement of IVL catheters, ensuring targeted shockwave delivery.
Integration minimizes procedural complications, reduces the need for repeat interventions, and enhances patient safety. As IVL technology continues to evolve, synergy with imaging modalities will contribute to more effective treatments, driving adoption and improving clinical outcomes in cardiovascular care.
The global intravascular lithotripsy (IVL) market is competitive, with several key players striving for market share. Leading companies, such as Shockwave Medical (Johnson & Johnson Services, Inc.), dominate the market by offering advanced IVL systems.
The market is characterized by rapid technological innovations, with companies focusing on improving the safety and effectiveness of their devices. Partnerships, acquisitions, and regulatory approvals are also vital strategies for growth.
Emerging players are exploring opportunities in underserved regions, while established players continue to expand their presence globally. Ongoing clinical trials and FDA approvals, like that of AVS's Pulse IVL™, further impel market dynamics.
Recent Developments in the Global Intravascular lithotripsy (IVL) Market
|
Attributes |
Details |
|
Forecast Period |
2024 to 2031 |
|
Historical Data Available for |
2019 to 2023 |
|
Market Analysis |
US$ Million for Value Volume for Units |
|
Key Regions Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product Type
By Application
By End-use Industry
By Region
To know more about delivery timeline for this report Contact Sales
The global market is estimated to increase from US$ 489.1 Mn in 2024 to US$ 1197.5 Mn by 2031.
Rising cardiovascular disease prevalence and technological advancements remain key factors for market growth.
Some of the top players in the market are Shockwave Medical (Johnson & Johnson Services, Inc.), Amplitude Vascular Systems, and Cardiovascular Systems, Inc. (CSI).
The market is projected to record a CAGR of 11.7% during the forecast period from 2024 to 2031.
A prominent opportunity lies in expanding treatment options for peripheral artery disease.
